Oncolytics completes continuance to BC; expects Nevada domestication by March 31

ONCOLYTICS BIOTECH INC

First step completed March 17: continuance from Alberta to British Columbia under BCBCA.
Second step expected March 31: domestication to Nevada; shares continue on Nasdaq as ONCY.
New CUSIP 68237V103 and ISIN US68237V1035 effective April 1; no name change.
Shareholder rights modified per BCBCA and will change under Nevada law; approved Jan 15, 2026.
Outstanding common shares unchanged; no impact on trading symbol or exchange listing.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ONCOLYTICS BIOTECH INC: Adopted continuation application with new Notice of Articles and Articles of Oncolytics British Columbia, changing governing documents from Alberta to British Columbia corporate law.

Change: charter amendment

Exact text from the filing

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

View on SEC.gov

41 governance changes filed in the last 30 days. Browse all governance changes →

ONCOLYTICS BIOTECH INC filing history →

Source: SEC EDGAR

accession 0001104659-26-032763

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.